YahooOctober 22, 2026 at 1:29 PM NY5 Days Ago
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven’s experimental spinocerebellar ataxia treatment.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
